Protein therapeutics company Sesen Bio Inc (Nasdaq:SESN) revealed on Monday the election of Dennis Kim, MD, MPH as its chief medical officer.
In this role, Dr Kim will oversee the continued Phase 3 development of Vicinium, Sesen Bio's lead targeted fusion protein, for patients with high-grade non-muscle invasive bladder cancer (NMIBC), as well as preparations for a marketing authorisation submission and pre-commercial activities.
Recently, Dr Kim has held senior and leadership roles at Ipsen, Spectrum, Novartis, Biogen Idec as well as Amgen.
Previously, Dr Kim worked as an epidemic intelligence service officer at the Centers for Disease Control and Prevention, where he played active roles in environmental and infectious disease studies.
Under Nasdaq Stock Market Listing Rule 5635(c)(4), Dr Kim received an option to purchase 425,000 shares of the company's common stock at an exercise price per share equal to the closing price per share of its common stock on The Nasdaq Global Market on 3 December 2018. The stock option will have a ten-year term and will vest over a four-year period, with 25% of the shares underlying the stock option award vesting on the first anniversary of the date of grant and an additional 6.25% of the shares underlying the stock option vesting at the end of each successive three-month period following the one-year anniversary of the date of grant of the stock options.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial